Compare TWAV & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWAV | CANF |
|---|---|---|
| Founded | N/A | 1994 |
| Country | United States | Israel |
| Employees | 7 | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5M | 6.0M |
| IPO Year | N/A | 2011 |
| Metric | TWAV | CANF |
|---|---|---|
| Price | $1.46 | $3.59 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | 167.8K | ★ 1.8M |
| Earning Date | 05-13-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $2,715,455.50 |
| Revenue Next Year | N/A | $101.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.58 | $0.17 |
| 52 Week High | $2.58 | $10.40 |
| Indicator | TWAV | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 44.51 | 55.17 |
| Support Level | $1.30 | $2.88 |
| Resistance Level | $1.94 | $4.74 |
| Average True Range (ATR) | 0.13 | 0.49 |
| MACD | -0.00 | 0.11 |
| Stochastic Oscillator | 28.00 | 29.82 |
TaoWeave Inc is a digital asset company. The company offers investors a regulated, publicly traded vehicle to gain exposure to the decentralized AI economy. The company aims to invest in the Bittensor ecosystem through partnerships with subnets, miners, and validators, and operates with zero debt by maintain appropriate cash reserves. The Company currently operates in three segments: (1) "Digital Assets", which represents the business surrounding treasury activity with Bittensor, (2) Collaboration Products which represents the business surrounding Mezzanine product offerings, and (3) Managed Services, which represents the business surrounding managed services for video collaboration and network solutions.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.